Naperville, IL -- (SBWIRE) -- 09/06/2013 -- Reportstack, provider of premium market research reports announces the addition of Myelodysplastic Syndrome - Pipeline Review, H2 2013 market report to its offering
Myelodysplastic Syndrome - Pipeline Review, H2 2013
Summary
, 'Myelodysplastic Syndrome - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Myelodysplastic Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome. Myelodysplastic Syndrome - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Myelodysplastic Syndrome.
- A review of the Myelodysplastic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Myelodysplastic Syndrome pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Myelodysplastic Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Companies Mentioned
Amgen Inc.
Athersys, Inc.
GlaxoSmithKline plc
Daiichi Sankyo Company, Ltd
medac GmbH
Merck & Co., Inc.
Dainippon Sumitomo Pharma Co., Ltd.
Gamida Cell Ltd.
Bio-Path Holdings, Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Pfizer Inc.
Sunesis Pharmaceuticals, Inc.
SuperGen, Inc.
Teva Pharmaceutical Industries Limited
Cyclacel Pharmaceuticals Inc.
Celgene Corporation
Incyte Corporation
4SC AG
Celldex Therapeutics, Inc.
Marshall Edwards, Inc.
MethylGene Inc
OXiGENE, Inc.
Telik, Inc.
Array BioPharma Inc.
Choongwae Pharma Corp
Synta Pharmaceuticals Corp.
BioAlliance Pharma SA
Clavis Pharma ASA
Cellerant Therapeutics, Inc.
Chroma Therapeutics Ltd.
Actinium Pharmaceuticals, Inc.
Acceleron Pharma, Inc.
BioMAS Ltd.
Apogenix GmbH
Stemline Therapeutics, Inc.
Cornerstone Pharmaceuticals, Inc.
Onconova Therapeutics, Inc
Concert Pharmaceuticals, Inc.
Tragara Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc.
EpiZyme, Inc.
To view the table of contents for this market research report please visit
http://www.reportstack.com/product/140895/myelodysplastic-syndrome-pipeline-review-h2-2013.html